Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$16.75 - $48.98 $58,759 - $171,821
-3,508 Reduced 23.68%
11,305 $232,000
Q2 2023

Aug 02, 2023

BUY
$40.65 - $59.54 $602,148 - $881,966
14,813 New
14,813 $696,000
Q1 2022

May 12, 2022

SELL
$30.71 - $45.71 $153,550 - $228,550
-5,000 Closed
0 $0
Q4 2021

Feb 02, 2022

BUY
$37.06 - $47.11 $185,300 - $235,550
5,000 New
5,000 $213,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.